Helix Biopharma Stock Shares Outstanding
| HBP Stock | EUR 1.15 0.00 0.00% |
HELIX BIOPHARMA fundamentals help investors to digest information that contributes to HELIX BIOPHARMA's financial success or failures. It also enables traders to predict the movement of HELIX Stock. The fundamental analysis module provides a way to measure HELIX BIOPHARMA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to HELIX BIOPHARMA stock.
HELIX |
HELIX BIOPHARMA Company Shares Outstanding Analysis
HELIX BIOPHARMA's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, HELIX BIOPHARMA has 0.0 of shares currently outstending. This indicator is about the same for the Other average (which is currently at 0.0) sector and about the same as Other (which currently averages 0.0) industry. This indicator is about the same for all Germany stocks average (which is currently at 0.0).
HELIX Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses HELIX BIOPHARMA's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of HELIX BIOPHARMA could also be used in its relative valuation, which is a method of valuing HELIX BIOPHARMA by comparing valuation metrics of similar companies.HELIX BIOPHARMA is currently under evaluation in shares outstanding category among its peers.
HELIX Fundamentals
| Current Valuation | 29.03 M | |||
| Price To Book | 50.71 X | |||
| EBITDA | (6.53 M) | |||
| Net Income | (6.56 M) | |||
| Cash Flow From Operations | (6.51 M) | |||
| Number Of Employees | 13 | |||
| Market Capitalization | 38.94 M | |||
| Total Asset | 3.73 M | |||
| Z Score | -3.3 | |||
| Net Asset | 3.73 M |
About HELIX BIOPHARMA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze HELIX BIOPHARMA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of HELIX BIOPHARMA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of HELIX BIOPHARMA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for HELIX Stock Analysis
When running HELIX BIOPHARMA's price analysis, check to measure HELIX BIOPHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HELIX BIOPHARMA is operating at the current time. Most of HELIX BIOPHARMA's value examination focuses on studying past and present price action to predict the probability of HELIX BIOPHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HELIX BIOPHARMA's price. Additionally, you may evaluate how the addition of HELIX BIOPHARMA to your portfolios can decrease your overall portfolio volatility.